Skip to main content
BRNS
NASDAQ Life Sciences

Barinthus Biotherapeutics Receives Nasdaq Delisting Extension, Moves to Capital Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.62
Mkt Cap
$26.184M
52W Low
$0.512
52W High
$2.92
52W Position info
21% above low
Off High info
79% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

BRNS sits 21% above its 52-week low of $0.512.

Summary

Barinthus Biotherapeutics received a Nasdaq delisting extension until December 28, 2026, but its shares were simultaneously moved to the Nasdaq Capital Market due to the ongoing sub-$1.00 bid price issue.


Key Events · Corporate Governance and Compliance · BRNS

  • Nasdaq Delisting Extension Granted

    The company received an additional 180 calendar days, until December 28, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.

  • Listing Transferred to Nasdaq Capital Market

    Effective July 2, 2026, the company's American Depositary Shares (ADSs) were transferred from the Nasdaq Global Market to the Nasdaq Capital Market, a lower tier.

  • Reverse Stock Split Under Consideration

    The company is actively monitoring its bid price and will consider options, including a reverse stock split, to resolve the deficiency and regain compliance.

  • Annual General Meeting Results

    Shareholders approved all matters submitted to a vote at the 2026 Annual General Meeting, including the re-election of directors and the re-appointment of auditors.


Analysis · BRNS · Life Sciences

Barinthus Biotherapeutics has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to December 28, 2026. However, this comes with a transfer of its listing from the Nasdaq Global Market to the Nasdaq Capital Market, a lower tier. The company is actively considering options, including a reverse stock split, to avoid eventual delisting, which remains a significant risk for this micro-cap company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRNS was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.2M. The 52-week trading range was $0.51 to $2.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRNS - Latest Insights

BRNS
Sep 01, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.800 info
Change: +$0.035 (+5%) info
Market Cap: $30.232M info
BRNS
Aug 25, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.603
Real-time Price: $0.800 info
Change: +$0.197 (+33%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:49 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5705
Real-time Price: $0.800 info
Change: +$0.2295 (+40%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.800 info
Change: +$0.210 (+36%) info
Market Cap: $30.232M info
BRNS
Jun 10, 2026, 5:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.665
Real-time Price: $0.800 info
Change: +$0.135 (+20%) info
Market Cap: $30.232M info